Apogee Therapeutics, Inc.
APGE
Rank in Stocks
#2356
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Share Price
$135.07
Last synced: 2026-09-04
Market Cap
$8.36B
Change (1 day)
0.00%
Change (1 year)
137.21%
Country
US
Trade Apogee Therapeutics, Inc. (APGE)
Category
Healthcare
Number of shares outstanding for Apogee Therapeutics, Inc. (APGE)
Number of shares outstanding as of June 2026: 75.44M
According to Apogee Therapeutics, Inc. latest financial reports and stock price the company's current number of shares outstanding is 75.44M. At the end of December 2023 the company had 50.66M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Apogee Therapeutics, Inc. (APGE) from 2022 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 75.44M | 36.69% |
| 2024 | 55.19M | 8.96% |
| 2023 | 50.66M | -0.04% |
| 2022 | 50.67M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | 236.54% |
US
|
|
| 396.00M | 424.90% |
US
|
|
| 478.91M | 534.80% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -17.57% |
NL
|
